لخّصلي

--- The capacity to trigger various immunological checkpoint pathways with immunosuppressive properties.According to Junli Zhao et al., PD-1/PD-L1 signaling in hippocampus neurons controls cognitive processes and synaptic transmission.Therefore, it is easy to see that pathogen-infected cells use the PD-1/PD-L1 axis to promote the occurrence of immune inflammation in the local tumor microenvironment, disrupting the immune balance of the organism and avoiding the host immune system's attack, based on the previously mentioned molecular regulatory mechanisms of the PD-1/PD-L1 signaling pathway.By primarily reducing the activity of effector T cells and boosting the function of immunosuppressive regulatory T cells (Tregs), the interaction between PD-1 and PD-L1 negatively regulates adaptive immune response.T cell effectiveness can be increased by blocking the PD-1/PD-L1 pathway, which increases the sensitivity of pathogen-infected cells to immune checkpoint blockade therapy (Fig.Furthermore, by blocking T cell signaling molecules' downstream signal transduction, PD-1 can affect glycolysis and other metabolic pathways, impeding cellular bioenergetics [27].Through the PD-1/PD-L1 inhibitory pathway, Tissue-Resident Memory T Cells regulate tissue immunological homeostasis and mediate protective immune responses in the human pancreas [26].1).[27].

--- The capacity to trigger various immunological checkpoint pathways with immunosuppressive properties. The two main immunological checkpoint molecules are thought to be programmed cell death ligands (PD-Ls) and programmed death protein 1 (PD-1). By primarily reducing the activity of effector T cells and boosting the function of immunosuppressive regulatory T cells (Tregs), the interaction between PD-1 and PD-L1 negatively regulates adaptive immune response. This helps to maintain immune homeostasis, which guards against dysregulated immunity and detrimental immune responses. However, in order to promote immune escape during the formation and progression of cancer, cancer cells take use of the PD-1/PD-L1 axis. Neutralizing antibodies that block PD-1/PD-L1 improve anti-tumor immunity and restore T cell function, leading to exceptional results in cancer treatment.
Consequently, there has been a growing interest in the regulation mechanisms of PD-1/PD-L1 in malignancies. The function of CD28 or other co-stimulatory molecules must be carefully taken into account by the primary targets of PD-1 signaling. Therefore, it is easy to see that pathogen-infected cells use the PD-1/PD-L1 axis to promote the occurrence of immune inflammation in the local tumor microenvironment, disrupting the immune balance of the organism and avoiding the host immune system's attack, based on the previously mentioned molecular regulatory mechanisms of the PD-1/PD-L1 signaling pathway. T cell effectiveness can be increased by blocking the PD-1/PD-L1 pathway, which increases the sensitivity of pathogen-infected cells to immune checkpoint blockade therapy (Fig. 1).
The PD-1 molecule is essential for both cellular motility and adhesion. Through PI3K/Akt, activated Tregs that have high levels of PD-1, PD-1/PD-L1 signaling control T cell migration across lymphatic endothelial cells in vivo [25]. The memory and persistence of immune responses are impacted by the regulation of memory T cell production by PD-1 binding to PD-L1. Through the PD-1/PD-L1 inhibitory pathway, Tissue-Resident Memory T Cells regulate tissue immunological homeostasis and mediate protective immune responses in the human pancreas [26]. Furthermore, by blocking T cell signaling molecules' downstream signal transduction, PD-1 can affect glycolysis and other metabolic pathways, impeding cellular bioenergetics [27].
[27]. Furthermore, PD-1 is physiologically important for the peripheral and central nervous systems. According to Junli Zhao et al., PD-1/PD-L1 signaling in hippocampus neurons controls cognitive processes and synaptic transmission. After traumatic brain injury, PD-1 inhibition reduces the loss of memory and learning [28].